1. Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3–5 months follow-up
- Author
-
Yonatan Oster, Iddo Z. Ben-Dov, Ruth Israeli, Dana G. Wolf, Aharon Bloch, Ashraf Imam, Ido Burstein, Abed Khalaileh, Michal Dranitzki Elhalel, Talia Alster, Raneem Bader, Keren Tzukert, Haya Asayag, Michal Aharon, Roy Abel, Esther Oiknine-Djian, Hadas Pri-Chen, and Irit Mor-Yosef Levi
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Peritoneal dialysis ,Lower risk ,End stage renal disease ,Cohort Studies ,End-stage renal disease ,Renal Dialysis ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,Renal replacement therapy ,Prospective Studies ,RNA, Messenger ,Dialysis ,BNT162 Vaccine ,Aged ,Viral infections ,Vaccines ,Vaccines, Synthetic ,business.industry ,SARS-CoV-2 ,Antibody titer ,COVID-19 ,medicine.disease ,Kidney Transplantation ,Vaccination ,Nephrology ,Hemodialysis ,Original Article ,Female ,mRNA Vaccines ,business ,Follow-Up Studies - Abstract
BackgroundDetermining the humoral immunogenicity of tozinameran (BNT162b2) vaccine in patients requiring chronic renal replacement therapy, and its impact on COVID-19 morbidity several months after vaccination, will guide risk assessment and subsequent changes in vaccination policy.MethodsIn a prospective post-vaccination cohort study with up to 5 months follow-up we studied outpatient dialysis and kidney transplant patients and respective healthcare teams. Outcomes were anti S1/S2 antibody response to vaccine or infection and infection rate during followup.Results175 dialysis patients (40% women, 65±15 years), 252 kidney transplant patients (33% women, 54±14 years) and 71 controls (65% women, 44±14 years) were followed. Three months or longer after vaccination we detected anti S1/S2 IgG antibodies in 80% of dialysis patients, 44% of transplant recipients and 100% of controls, whereas respective rates after infection were 94%, 75% and 100%. Predictors of non-response were older age, diabetes, history of cancer, lower lymphocyte count and lower vitamin-D levels. Factors associated with lower titers in dialysis patients were modality (hemodialysis vs peritoneal) and high serum ferritin levels. In transplant patients, hypertension and higher calcineurin or mTOR inhibitor drug levels were linked with diminished antibody response. Vaccination associated with fewer subsequent infections (HR=0.23, p10titer (pConclusionsDialysis patients, and more so kidney transplant recipients, mounted reduced antibody response to COVID-19 mRNA vaccination, and lesser humoral response associated with more infections. Measures to identify and protect non-responsive patients are urgently required.SignificanceReports on the humoral immunogenicity of SARS-CoV-2 mRNA vaccines in patients with end stage renal disease are scarce, and association with subsequent COVID-19 morbidity is unknown. In this cohort study that included 175 patients treated with dialysis, 252 kidney transplant recipients and 71 control volunteers, the proportion achieving an antibody response was time- and group-dependent, reaching 80%, 44% and 100% at 3 months post prime inoculation. Personal history of vaccination, positive antibody responses and antibody titers associated with significantly lower risk of COVID-19 infection. Thus, in patients with end stage renal disease, SARS-CoV-2 antibody testing may be warranted after vaccination, to identify non-responders at higher risk for disease.
- Published
- 2022